GlassScriptPhysician profile
Erika Robinson
NPI 1245823129
$4,353.22
in general payments reported to CMS, 2019-2025
21 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $609 · 2022: $1,122 · 2023: $1,548 · 2024: $953 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,583 · Education: $39.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,582.60 |
| Education | $39.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $888.30 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Abbvie INC. | $790.69 | 2021-2024 | |
| Gilead Sciences, INC. | $670.75 | 2022-2024 | Biktarvy |
| Janssen Biotech, INC. | $457.99 | 2021-2023 | Symtuza |
| Theratechnologies INC. | $403.00 | 2021-2023 | Egrifta, Trogarzo, Egrifta Sv |
| Merck Sharp & Dohme LLC | $370.38 | 2021-2024 | Recarbrio, Dificid, Zerbaxa |
| Paratek Pharmaceuticals, INC. | $145.54 | 2023-2024 | Nuzyra |
| Melinta Therapeutics, LLC | $123.14 | 2021-2024 | Vabomere, Rezzayo, Kimyrsa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.22 | 2021-2023 | Xifaxan |
| Ferring Pharmaceuticals INC. | $74.07 | 2022-2023 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $64.31 | 2021-2023 | Gattex |
| Lilly USA, LLC | $47.50 | 2022 | |
| Napo Pharmaceuticals INC | $46.97 | 2023 | Mytesi |
| Boston Scientific Corporation | $35.25 | 2023 | Upsylon |
| Lifescan, INC. | $29.73 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $24.62 | 2022 | |
| Astellas Pharma US INC | $22.99 | 2023 | Cresemba |
| Insmed, INC. | $22.09 | 2024 | Arikayce |
| Vyera Pharmaceuticals, LLC | $21.76 | 2022 | |
| La Jolla Pharmaceutical Company | $17.74 | 2022 | |
| Pharming Healthcare, INC. | $17.18 | 2023 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.